Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
CAMBRIDGE, Mass., July 5, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better…
NEW YORK, July 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA, AGRX, MULN, EVFM, and ENDP. To…
Gainers
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday.
read more...…
Some of the stocks that may grab investor focus today are:
read more...…
Akebia Therapeutics Inc (NASDAQ: AKBA) shares are surging in Thursdays after-hours session after the company executed an agreement to terminate its Vadadustat…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia Akebia to assume responsibility for…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
CAMBRIDGE, Mass., June 3, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better…
CAMBRIDGE, Mass., June 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better…
read more...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
NEW YORK, May 13, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on…
NEW YORK, May 12, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the…
NEW YORK, May 11, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics,…
NEW YORK, May 10, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed…
NEW YORK, May 6, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on…
NEW YORK, May 5, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the…
NEW YORK, May 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akebia…
Akebia to Host Conference Call to Provide Business Update CAMBRIDGE, Mass., May 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq:…
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders: The Law Offices of Vincent…
NEW YORK, April 29, 2022 /PRNewswire/ -- WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the…
NEW YORK, April 28, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the…
NEW YORK, April 27, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics,…
NEW YORK, April 25, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akebia…
NEW YORK, April 25, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders: The Law Offices of Vincent…
NEW YORK, April 21, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the…
NEW YORK, April 20, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of…
NEW YORK, April 20, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics,…
NEW YORK, April 19, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed…
NEW YORK, April 18, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders: The Law Offices of Vincent…
NEW YORK, April 15, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on…
NEW YORK, April 13, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of…
NEW YORK, April 13, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics,…
NEW YORK, April 12, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed…
NEW YORK, April 11, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akebia…
NEW YORK, April 11, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders: The Law Offices of Vincent…
NEW YORK, April 8, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on…
Akebia Therapeutics Inc (NASDAQ: AKBA) announced three poster presentations at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022.
Latest…
read more...…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
NEW YORK, April 7, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the…
NEW YORK, April 6, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of…
NEW YORK, April 6, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics,…
NEW YORK, April 5, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed…